Why the study?
Does a biventricular assist device improve hemodynamics and allow for cardiac recovery in acute doxorubicin-induced cardiotoxicity?
Does a biventricular assist device improve hemodynamics and allow for cardiac recovery in acute doxorubicin-induced cardiotoxicity?
Biventricular assist devices may provide effective short-term mechanical circulatory support for patients with acute heart failure resulting from doxorubicin-induced cardiomyopathy.
Hypothesis-generating for temporary BiVAD in doxorubicin cardiotoxicity; prospective studies required before clinical adoption.
This report describes a patient treated for metastatic leiomyosarcoma, who acutely developed doxorubicin-induced cardiotoxicity, and consequently developed heart failure. Medical therapy was initiated; however, her condition deteriorated and a surgical alternative was proposed. A biventricular assist device was implanted, allowing her multisystem organ failure to improve. During the next 9 days while on the assist device, her heart failure resolved, her organs were well perfused, and her heart entered a recovery period. After 9 days of mechanical support with the biventricular assist device, she was explanted from the assist device, and with inotropic support and an intra-aortic balloon pump, she maintained adequate hemodynamics. Eighteen days after implantation of the assist device, she was discharged from the hospital with hospice care, where she later died. Although the patient's cardiac function did not have long-term recovery, short-term recovery after doxorubicin toxicity was achieved. The authors maintain that the use of a biventricular assist device in the treatment of acute heart failure resulting from doxorubicin-induced cardiomyopathy is an effective way to manage this patient population.
No takes yet. Share an insight, caveat, or question.
Swartz et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: